Headlines at Hopkins: news releases from across
university Headlines
News by Topic: news releases organized by
subject News by Topic
News by School: news releases organized by the 
university's 9 schools & divisions News by School
Events Open to the Public (campus-wide) Events Open
to the Public
Blue Jay Sports: Hopkins Athletic Center Blue Jay Sports
Search News Site Search the Site

Contacting the News Staff: directory of
press officers Contacting
News Staff
Receive News Via Email (listservs) Receive News
Via Email
Resources for Journalists Resources for Journalists

Virtually Live@Hopkins: audio and video news Virtually
Hopkins in the News: news clips about Hopkins Hopkins in
the News

Faculty Experts: searchable resource organized by 
topic Faculty Experts
Faculty and Administrator Photos Faculty and
Faculty with Homepages Faculty with Homepages

JHUNIVERSE Homepage JHUniverse Homepage
Headlines at Hopkins
Media Advisory

Office of News and Information
Johns Hopkins University
3003 N. Charles Street, Suite 100
Baltimore, Maryland 21218-3843
Phone: (410) 516-7160 | Fax (410) 516-5251

February 25, 2003
To: Reporters, Editors, Producers
Fr: Michael Purdy
Senior science writer
(410) 516-7906
Re: New contraceptive microbicide in clinical trials

Researchers at the Johns Hopkins University and ReProtect LLC have developed a gel that may both help block the spread of sexually transmitted diseases and reduce unwanted pregnancies.

The compound, known as BufferGel, is currently in advanced clinical trials for its ability to prevent pregnancy. Trials of its ability to block HIV transmission are scheduled to be under way soon.

When applied vaginally prior to intercourse, BufferGel maintains vaginal acidity at its normal levels, which can kill both sperm and many germs. A video news release on BufferGel is available online at www.jhu.edu/news_info/news/audio-video/buffergel.html.

Videotape copies of the news release are also available on request. A press release on BufferGel is online at www.jhu.edu/news_info/news/home02/jan02/germs.html.

Note: Professor Richard Cone is a part-owner of ReProtect LLC. His financial interests in this research are being managed by the Johns Hopkins University in accordance with its conflict-of- interest policies. The clinical trials are funded by the National Institutes of Health.

Johns Hopkins University news releases can be found on the World Wide Web at http://www.jhu.edu/news_info/news/
   Information on automatic e-mail delivery of science and medical news releases is available at the same address.

Go to Headlines@HopkinsHome Page